Synexus and Radiant Research Announce Merger
Synexus and Radiant Research are merging their operations to form a single global site network of 185 sites with 1,500 employees.
Synexus and Radiant Research are merging their operations to form a single global site network of 185 sites with 1,500 employees. The enlarged entity will retain the Synexus name.
“We are delighted to be working together with the Radiant team,” said Christophe Berthoux, who has been chief executive officer for Synexus since 2010 and will lead the new company. “Best practices from Synexus, Radiant and our earlier acquisition of Research Across America will be incorporated across our global network of sites.”
Mike Clay will lead the U.S. operations of the combined business, reporting directly to Berthoux.
The new business will span 11 countries, offering access to more than 100 million patients in clinical development markets, and it will provide data-driven site selection and activation, combined with proven patient engagement and retention expertise across the U.S., Europe and Africa, according to Synexus.
Philip Ward is the European Editor for Applied Clinical Trials
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Oveporexton Shows Superior Efficacy in Phase II Narcolepsy Type 1 Trial Without Hepatotoxicity
May 16th 2025In the TAK-861-2001 Phase IIb study, oveporexton significantly improved wakefulness, daytime sleepiness, and cataplexy frequency in patients with narcolepsy type 1, outperforming current therapies and avoiding liver toxicity seen with earlier OX2R agonists, according to results published in The New England Journal of Medicine.
